MoonLake Immunotherapeutics (MLTX) CFO receives 354,296-share restricted stock grant

Rhea-AI Filing Summary

MoonLake Immunotherapeutics reported that its Chief Financial Officer, Matthias Bodenstedt, received an award of 354,296 Class A ordinary shares on January 7, 2026. The shares were granted at a price of $0 per share as restricted stock, meaning they are subject to vesting conditions rather than being fully transferable immediately.

According to the filing, these restricted shares will vest in four equal annual installments on January 7, 2027, 2028, 2029 and 2030, as long as he continues to serve the company through each vesting date. After this grant, Bodenstedt beneficially owned a total of 1,276,305 Class A ordinary shares, all held directly.

Insights

Equity compensation and governance analyst

MoonLake CFO receives a sizable multi-year restricted stock award.

The filing shows that MoonLake Immunotherapeutics granted its CFO, Matthias Bodenstedt, 354,296 Class A ordinary shares as restricted stock at $0 per share on January 7, 2026. This is equity-based compensation rather than an open-market purchase or sale, so it does not reflect a change in his cash investment but does increase his equity stake.

The award vests in four equal annual installments on January 7, 2027, 2028, 2029 and 2030, contingent on his continued service. That structure is typical of long-term incentive plans, tying value realization to ongoing tenure. Following the grant, he beneficially owned 1,276,305 Class A ordinary shares directly, indicating a meaningful alignment with common shareholders, though the filing does not quantify this as a percentage of the company.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bodenstedt Matthias

(Last) (First) (Middle)

C/O MOONLAKE IMMUNOTHERAPEUTICS

DORFSTRASSE 29

(Street)

ZUG V8 6300

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MoonLake Immunotherapeutics [ MLTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/07/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A ordinary shares, par value $0.0001 per share	01/07/2026		A(1)		354,296	A	$0	1,276,305	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of restricted stock that vest in four equal annual installments on January 7, 2027, 2028, 2029 and 2030, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date.

	/s/ Matthias Bodenstedt	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did MoonLake Immunotherapeutics (MLTX) disclose?

MoonLake Immunotherapeutics disclosed that its Chief Financial Officer, Matthias Bodenstedt, received 354,296 Class A ordinary shares as a restricted stock grant on January 7, 2026 at a price of $0 per share.

Is the MoonLake (MLTX) CFO stock award immediately vested?

No. The filing states that the 354,296 restricted shares vest in four equal annual installments on January 7, 2027, 2028, 2029 and 2030, subject to the CFO’s continued service to the company through each vesting date.

How many MoonLake (MLTX) shares does the CFO own after this Form 4 transaction?

After the reported grant, Chief Financial Officer Matthias Bodenstedt beneficially owned 1,276,305 Class A ordinary shares of MoonLake Immunotherapeutics, held directly.

Was this MoonLake (MLTX) insider transaction a purchase or a grant?

The transaction was reported with code "A", and the shares were issued at $0 per share as restricted stock, indicating an equity grant as compensation rather than an open-market purchase.

Does the MoonLake (MLTX) CFO’s restricted stock grant depend on continued employment?

Yes. The filing explains that the restricted shares vest over time only if the Reporting Person continues to provide service to MoonLake Immunotherapeutics through each vesting date in 2027, 2028, 2029 and 2030.

Are the MoonLake (MLTX) CFO’s shares held directly or through another entity?

The Form 4 indicates that the 1,276,305 Class A ordinary shares beneficially owned after the transaction are held with direct ownership, with no separate entity listed in the nature of ownership field.